Novel therapies for metastatic castrate-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Novel therapies for metastatic castrate-resistant prostate cancer.

Novel therapies for metastatic castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q34249263

about

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Renin-angiotensin system blockade: Its contribution and controversy Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment Androgen receptor in human endothelial cells.Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.The biology of castration-resistant prostate cancer STAMP2 increases oxidative stress and is critical for prostate cancer.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.A changing landscape in castration-resistant prostate cancer treatment Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters The stroma-a key regulator in prostate function and malignancy Advances in androgen receptor targeted therapy for prostate cancer Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer.The management of pain in metastatic bone disease.Clinical usefulness of bone markers in prostate cancer with bone metastasis.Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.A multi-targeted approach to treating bone metastases.Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network.Development of enzalutamide for metastatic castration-resistant prostate cancer.Synthesis of novel oleanolic acid and ursolic acid in C-28 position derivatives as potential anticancer agents.Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.

P2860

Q26825053-DE0A3D15-1F5A-4950-AF15-DA79BFEAD831 Q26827221-6A0FA25F-6475-419E-B353-FF001664839D Q26853374-6F3310F3-4DC5-40B4-8B84-602DA2430A63 Q27304922-A0A3AA3B-8080-44AB-946D-A3E6094536C0 Q28388750-33665841-5492-44DC-A73A-D0B7E07E1306 Q28484299-CD67419B-0FE0-4AFF-BDEF-BD3001588E78 Q28484572-59F9BEF8-C702-4022-A439-13572320944B Q30393012-CE21A8D2-4B68-452C-A0A7-AE24D71332C1 Q30416201-ECE0FB10-938A-443F-956C-FC6401E008EC Q33882116-8BD9C3AE-A2A0-4350-8B10-5E2110A01204 Q34042948-F66F8ED3-B5AE-415B-8C91-213667A7BF63 Q34412589-CAD871A8-CD54-46E1-ADF1-4A59542A918D Q34749943-5D7711C9-F3A2-414F-B88E-7A28483EA9D0 Q35039889-1F372518-69DC-4ECA-A125-15D1A1704499 Q35192455-48B90C7E-9DE7-4880-85A3-B502160A2A75 Q35985270-FA0DA033-7695-4B5C-9E99-4DFB9D6E39A4 Q36101308-56B0835E-4FDF-4FEC-84A2-F35288D42898 Q36165436-3CB1CCAD-4A9F-45D4-861A-1CDC469F40C0 Q36385066-4270A9F4-1C0F-45B0-A91D-712150B6FF21 Q36446486-DFCE4603-F6AC-461F-BB15-A3CCEB473E46 Q36557246-673C4F9D-DB15-4FA4-9160-D3D4123CED91 Q36688923-D6DCA2AF-8B07-4DBF-A6B6-AA73BBDD9FA4 Q36776738-F90EACA9-54DB-4BA6-B9DC-2CC67A1E847A Q36783835-A2FF6E7E-44A0-4E36-93EE-A436C5C755F4 Q37017028-75E50378-7972-44DD-B5AE-4ABD46C01F24 Q37337217-CF5BDEF8-3F70-4913-B484-E41F865739FD Q37338567-9647ED26-4E3F-4AF3-9B66-2555F6FACFB3 Q37443603-F5550195-FA9C-43E3-9710-A46ED838B782 Q37537958-AEAF8EF6-B793-4162-B17D-8800C1BEDE1F Q37577433-B8B23851-4ED3-4DA9-8261-3CBACEC59016 Q37618071-8DBC6922-AA9E-4C21-A76B-DF37DA909BB1 Q38001278-08A8B334-7E59-42FC-9A25-F535744CF72A Q38026966-5026091E-AE84-474C-9372-6AFE480768F2 Q38090562-CF3D5C11-C053-4127-A8C7-BCBE20186AB1 Q38097373-48C178D0-5E36-4467-AA98-ABF02E943D5C Q38175846-DCC0B4C6-FDA4-4798-9598-5425D2D37CBE Q38314425-3390AE2C-DEFC-4FC8-B510-C78683AB6322 Q38589130-882BAA4D-9863-4378-B910-9381BED4BF14 Q38720610-E992C929-23CF-4B53-A7C5-F565810F5C13 Q38822335-F8E0F879-007A-4D3E-A7C2-8255F2FA74C9

P2860

Novel therapies for metastatic castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q34249263

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Novel therapies for metastatic castrate-resistant prostate cancer.

@ast

Novel therapies for metastatic castrate-resistant prostate cancer.

@en

Novel therapies for metastatic castrate-resistant prostate cancer.

@nl

type

label

Novel therapies for metastatic castrate-resistant prostate cancer.

@ast

Novel therapies for metastatic castrate-resistant prostate cancer.

@en

Novel therapies for metastatic castrate-resistant prostate cancer.

@nl

prefLabel

Novel therapies for metastatic castrate-resistant prostate cancer.

@ast

Novel therapies for metastatic castrate-resistant prostate cancer.

@en

Novel therapies for metastatic castrate-resistant prostate cancer.

@nl

P1433

Q34249263-E76BCAE4-764F-4583-8A77-314425FD5C44

P1476

Q34249263-92AC1D50-C789-4E4D-8334-977F1E836563

P2093

Q34249263-00FA3B97-91B8-4F91-A639-B463A7EDF144

Q34249263-3F2E2FB2-2B1A-4AFB-BAFD-F5542E62C56C

Q34249263-79CB891A-CF63-436E-9FA6-7D377279D69D

Q34249263-94475932-2375-4BDF-8468-AC0570F7C0DF

P2860

Q34249263-01985F5A-C86A-4C92-8190-9CA57B72D376

Q34249263-01AAE7BE-2D39-4CAC-8B00-277A9900CA84

Q34249263-02E38C81-381D-4539-A5C9-00E1ACB1DE76

Q34249263-038FD21E-86C5-404D-8953-0720C9645F7F

Q34249263-04155B8C-D719-436A-BB44-104AA77234AA

Q34249263-0A606D3F-32CE-486F-9793-8DFEF51F8A68

Q34249263-0B87B420-3074-4286-A97D-8E52466D1657

Q34249263-0E97BD62-B6E1-4223-A970-772D1D456599

Q34249263-125D91A8-7B01-4728-B16A-8A49A97A7BCE

Q34249263-12CACD4A-3682-4E33-9267-55F2C2ED1060

P304

Q34249263-EFB6C977-E493-4C7C-A110-44B20136D7DD

P31

Q34249263-574C390C-2B8E-40CC-80AA-0EDD73F90D6C

P356

Q34249263-33E0D58E-8058-4331-9039-BD5F0D9992A0

P407

Q34249263-0C775662-5953-4D9F-9C09-8EDF39F84690

P433

Q34249263-A4A1F854-B4DB-41D4-8E11-1531A6541D0A

P478

Q34249263-3144BBCB-DB70-4D66-B3BF-D007699706F2

P577

Q34249263-2F6D7D27-36AB-43ED-BD1F-EA1CDCEB5083

P5875

Q34249263-632DD975-6A20-4772-BC3F-1E45D52C8070

P698

Q34249263-F9D57DB6-72E5-44A3-9F98-B420A3D3D253

P932

Q34249263-AC3DB4FC-1EC7-4452-AB9E-D59A86B92354

P356

P1433

Journal of the National Cancer Institute

P1476

Novel therapies for metastatic castrate-resistant prostate cancer.

@en

P2093

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Farshid Dayyani

http://www.w3.org/2001/XMLSchema#string

Gary E Gallick

http://www.w3.org/2001/XMLSchema#string

Paul G Corn

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Outcomes of localized prostate cancer following conservative management

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Met, metastasis, motility and more

Prostate cancer and the met hepatocyte growth factor receptor

P304

1665-1675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR362

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51643169

http://www.w3.org/2001/XMLSchema#string

P698

21917607

http://www.w3.org/2001/XMLSchema#string

P932

4176261

http://www.w3.org/2001/XMLSchema#string